Company Description
Scienture Holdings, Inc. operates as pharmaceutical company that focuses on development and commercialization of products for the treatment of central nervous system and cardiovascular diseases in the United States.
The company operates through Integra and Scienture segments. The Integra segment engages in the wholesale and sale of licensed pharmaceutical brand, generic, and non-drug products.
The Scienture segment researches and develops branded pharmaceutical products. The company develops SCN-102, an oral liquid formulation of losartan potassium that is in phase 1 for the treatment of hypertension, diabetic nephropathy, and reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy; and SCN-104, a multi-dose dihydroergotamine mesylate (DHE) injection pen.
It also develops SCN-106, which is a thrombolytic agent that binds to fibrin in clots and converts entrapped plasminogen to plasmin; and SCN-107, a long-acting injection suspension formulation of a non-opioid analgesic for postsurgical local and regional analgesia.
Scienture Holdings, Inc. is based in Tampa, Florida.
| Country | United States |
| Founded | 2010 |
| IPO Date | Feb 13, 2020 |
| Industry | Pharmaceutical Retailers |
| Sector | Healthcare |
| Employees | 19 |
| CEO | Surendra Ajjarapu |
Contact Details
Address: 6308 Benjamin Rd, Suite 708 Tampa, Florida 33634 United States | |
| Phone | 800 261 0281 |
| Website | scienture.com |
Stock Details
| Ticker Symbol | SCNX |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001382574 |
| ISIN Number | US80880X1046 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Shankar Hariharan Ph.D. | Founder and Chief Executive Officer of Scienture LLC and Director |
| Surendra K. Ajjarapu | Chairman of the Board, Chief Executive Officer and Secretary |
| Prashant Patel R.Ph. | President and Chief Operating Officer |
| Rahul Surana M.B.A., Ph.D. | Executive Vice President and Chief Operating Officer of Scienture LLC |
| Michele Rath | Senior Vice President and Chief Commercial Officer of Scienture LLC |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 24, 2025 | 424B3 | Prospectus |
| Apr 11, 2025 | EFFECT | Notice of Effectiveness |
| Apr 11, 2025 | 424B3 | Prospectus |
| Apr 11, 2025 | 8-K | Current Report |
| Apr 4, 2025 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Mar 26, 2025 | 10-K | Annual Report |
| Mar 21, 2025 | 8-K | Current Report |
| Mar 18, 2025 | DRS | [Cover] Draft Registration Statement |
| Mar 13, 2025 | 8-K | Current Report |
| Mar 10, 2025 | 8-K | Current Report |